We offer real experts, solving real forecasting challenges quickly and delivering solutions in real time.
The flexibility of scaling your team as required, or bolt-on skills you don’t have in-house.
Our focus is on achieving optimal results, enhancing your forecasting efforts, and upskilling your team.
Our experienced consults provide tailored, scalable support, whether you need help validating assumptions, building models, or aligning global teams. We can provide structure and expertise when it matters most, from early pipeline planning and long-range forecasting, through launch and lifecycle management.
We help with:
Save internal bandwidth
Ensure strategic alignment
Accelerate timeframes
Reduce forecast risk
Whether you need a targeted scenario analysis or a fully bespoke forecasting and valuation model, our team builds custom solutions tailored to your asset, market, and decision context. We combine trusted data, transparent assumptions, and expert judgment to deliver models that support confident planning, investment decisions, and stakeholder alignment.
What is the true commercial potential of this asset under different scenarios?
Which assumptions matter most, and how sensitive are outcomes to changes in the market or competitive landscape?
How can we customize a model to reflect our specific strategy, timing, and risk profile?
How do we create a flexible, auditable model that supports internal decision-making and external discussions?
From validating an existing forecast, preparing critical decisions, to seeking to improve consistency across teams, our Forecasting Audit Service delivers objective clarity and actionable insight. Through expert review of methodologies, benchmarking, and stakeholder engagement, we help identify strengths, uncover gaps, and optimize forecasting processes.
How robust and fit for purpose are our current forecasting methodologies and assumptions?
Where are the biggest drivers of risk, uncertainty, or inefficiency in our models?
How do our forecasts compare to best practices and external benchmarks?
How can we empower teams with the skills, tools, and alignment needed for consistent, high-quality forecasting?
Every strategic challenge is different. If you’re facing a unique commercial question or need tailored support beyond standard solutions, our consulting team will work with you to design an approach that fits your objectives, timelines, and data needs.
Hear directly from our consulting experts on how we work with clients, approach complex challenges, and deliver insight‑led support across the commercial lifecycle.
Our experts will help you identify the tools and insights that support your strategic, commercial, or investment priorities.
Paul leads the Evaluate’s consulting and analytics business, overseeing strategic advisory engagements across portfolio strategy, asset strategy, competitive intelligence, forecasting, valuation, and BD&L, working with clients across the global pharma and biotech ecosystem.
Paul brings extensive experience spanning academic research and life sciences consulting, supporting organizations ranging from early-stage biotech companies to large pharmaceutical corporate strategy teams. His work focuses on helping clients make evidence-based decisions across the product lifecycle, from pipeline prioritization through to commercial strategy and investment decision-making.
Ben specializes in quantitative analysis, leading projects covering buy and sell side due diligence, deal benchmarking, pipeline tracking, competitor analysis and product forecasting across a broad range of indications and markets, with an increasing focus on rare diseases. Recent work has included building prioritization models that can be used to identify in-licensing opportunities, out licensing partners, attractive indications, or technologies. Ben has authored multiple peer-reviewed journal articles and industry standard guideline documents.
Mark leads client engagements focused on asset strategy, portfolio prioritization, opportunity assessment, forecasting and valuation, and development strategy across pharma and biotech portfolios. Mark brings over 25 years of biopharma and life sciences experience, having worked across academia, large pharma, and consulting roles. His background includes hands-on experience as a medicinal chemist, followed by senior analytical and advisory positions supporting strategic decision-making in R&D and commercial planning.
As a neuroscientist, consultant and commercial leader, Kelly brings more than 16 years of experience in the life sciences sector. She partners with insights, analytics, and commercial strategy teams to transform how pharmaceutical organizations capture and operationalize market intelligence. At Evaluate, Kelly focuses on creative solutioning, bringing together life science consultants, data scientists, and subject‑matter experts to build custom intelligence programs and products that leverage the full breadth of Norstella’s assets, including gold-standard forecasting, real‑world data, market access insights, and expert journalistic intelligence. With expertise in competitive landscape analysis, tech-enabled secondary monitoring, primary research, and comprehensive conference coverage, her work supports translation of complex market signals into clear, actionable insights. Kelly holds a PhD in Neuroscience from Georgetown University and completed a postdoctoral fellowship at the National Institute of Neurological Disorders and Stroke (NINDS).
Markella brings 20 years of industry and consulting experience, with deep knowledge and expertise in oncology, rare disease and ophthalmology. She specializes in CI landscaping projects in specialty indications and has led our largest CI monitoring projects since 2020. She has led Norstella’s largest conference coverage engagements with Top 10 Pharma clients and brings on-the-ground, secondary and primary CI expertise. She holds an MBA from Baruch College and a master’s in biotechnology from Columbia University.
Get in touch with our team to explore the right solutions for your business.
